

OFFER OPENING ADVERTISEMENT FOR THE BUYBACK OF EQUITY SHARES OF AUROBINDO PHARMA LIMITED. UNDER THE SECURITIES AND EXCHANGE BOARD OF INDIA (BUYBACK OF SECURITIES) REGULATIONS, 2018 (AS AMENDED), ("BUYBACK REGULATIONS") FOR THE ATTENTION OF EQUITY SHAREHOLDERS / BENEFICIAL OWNERS OF THE EQUITY SHARES OF AUROBINDO PHARMA LIMITED.



AUROBINDO
Committed to healthier life!

AUROBINDO PHARMA LIMITED

Corporate Identity Number (CIN): L24239TG1986PLC015190

Registered Office: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana, India

Corporate Office: Galaxy, Floors: 22-24, Plot No.1, Survey No. 83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad - 500 032, Telangana, India

Tel.: +91 40 2373 6370/ 2374 7340; **Fax:** +91 40 2374 1080/ 2374 6833

Website: www.aurobindo.com; **Email:** cs@aurobindo.com

Contact Person: Mr. B. Adi Reddy, Company Secretary and Compliance Officer

OFFER TO BUYBACK UP TO 54,23,728 (FIFTY FOUR LAKH TWENTY THREE THOUSAND SEVEN HUNDRED AND TWENTY EIGHT) EQUITY SHARES AT A PRICE OF ₹ 1,475/- (RUPEES ONE THOUSAND FOUR HUNDRED AND SEVENTY FIVE ONLY) PER EQUITY SHARE, PAYABLE IN CASH, ON A PROPORTIONATE BASIS THROUGH THE TENDER OFFER ROUTE USING THE STOCK EXCHANGE MECHANISM FOR AN AGGREGATE CONSIDERATION OF UP TO ₹ 800,00,00,000/- (RUPEES EIGHT HUNDRED CRORE ONLY), (THE "BUYBACK") EXCLUDING TRANSACTION COSTS.

The Company has sent the letter of offer and Tender Form, along with the share transfer form, dated **Tuesday, April 21, 2026 ("Letter of Offer"/"LOF")**, in relation to the Buyback, through electronic means on Tuesday, April 21, 2026 to all Eligible Shareholders holding Equity Shares as on the Record Date i.e. Friday, April 17, 2026, whose e-mail IDs are registered with the Company or Depositories, in accordance with the Buyback Regulations and such other circulars or notifications, as may be applicable. Further, in terms of Regulation 9(ii) of the Buyback Regulations, if a request is received from any Eligible Shareholder for a physical copy of the Letter of Offer, the same shall be dispatched physically by registered post/ speed post/ courier.

For the detailed schedule of activities in relation to the Buyback, please refer to the Letter of Offer. A brief schedule of activities for the Buyback is as below:

BUYBACK OPENS ON	THURSDAY, APRIL 23, 2026
BUYBACK CLOSES ON	WEDNESDAY, APRIL 29, 2026
LAST DATE OF RECEIPT OF COMPLETED TENDER FORMS AND OTHER SPECIFIED DOCUMENTS BY THE REGISTRAR TO THE BUYBACK	WEDNESDAY, APRIL 29, 2026 (ON OR BEFORE 5.00 PM (IST))

The entitlement ratio for Eligible Shareholders is as below:

CATEGORY OF ELIGIBLE SHAREHOLDERS	BUYBACK ENTITLEMENT*
Reserved category for Small Shareholders	7 Equity Shares out of every 61 Equity Shares held on the Record Date
General category for all other Shareholders	2 Equity Shares out of every 249 Equity Shares held on the Record Date

*For further information in relation to the entitlement ratio for the Buyback in each category, see the section titled "Process and Methodology for the Buyback" in the Letter of Offer.

ELIGIBLE SHAREHOLDERS CAN ALSO CHECK THEIR ENTITLEMENT ON THE WEBSITE OF THE REGISTRAR TO THE BUYBACK BY FOLLOWING THE STEPS GIVEN BELOW:


1. Click on <https://kosmic.kfintech.com/karisma/buybackofferv2.aspx>
2. Select the name of the Company – **Aurobindo Pharma Limited**.
3. Select holding type – "Physical" or "NSDL" or "CDSL" or "PAN".
4. Based on the option selected above, enter your "Folio Number" or "NSDL DPID/Client ID" or "CDSL Client ID" or "PAN".
5. Click on submit.
6. Click on 'View' button.
7. The entitlement will be provided in the pre-filled 'FORM OF ACCEPTANCE-CUM ACKNOWLEDGEMENT'.

A copy of the Letter of Offer is available on the Company's website (www.aurobindo.com), on the website of the Registrar (<https://kosmic.kfintech.com/karisma/buybackofferv2.aspx>) and on the website of Manager to the Buy-back (www.axiscapital.co.in).

CORRIGENDUM TO PUBLIC ANNOUNCEMENT

In paragraph 4.3.2 of the public announcement dated April 7, 2026 and published on April 8, 2026, the premium over the volume weighted average market price of the Equity Shares on BSE during the 2 (Two) weeks preceding the Intimation Date should be read as 12.72% instead of 13.18%.

Capitalised terms used but not defined in this Advertisement shall have the meaning ascribed to such terms in the Letter of Offer.

MANAGER TO THE OFFER	REGISTRAR TO THE OFFER
 <p>AXIS CAPITAL LIMITED 1st Floor, Axis House, P. B. Marg, Worli, Mumbai - 400 025, Maharashtra, India Tel.: +91 22 4325 2183 Fax: +91 22 4325 3000 Contact Person: Harish Patel/ Simran Gadh Email: apl.buyback@axiscap.in Website: www.axiscapital.co.in SEBI Registration Number: INM000012029 CIN: U51900MH2005PLC157853</p>	 <p>KFin Technologies Limited Address: Selenium Tower B, Plot No. 31 and 32, Financial District, Nanakramguda, Serilingampally Hyderabad - 500 032, Telangana, India. Telephone Number:+91 40 6716 2222 Fax no.: +91 40 6716 1563; Tollfree no.: 18003094001 Website: www.kfintech.com E-mail: aurobindo.buyback2026@kfintech.com Investor Grievance Email: einward.ris@kfintech.com Contact Person: M. Murali Krishna SEBI Registration Number: INR000000221 CIN: L72400MH2017PLC444072</p>

For and on behalf of the Board of Directors of Aurobindo Pharma Limited

Sd/-

K. Nithyananda Reddy
Managing Director
DIN: 01284195

Sd/-

M. Madan Mohan Reddy
Whole-time Director
DIN: 01284266

Sd/-

B. Adi Reddy
Company Secretary and Compliance Officer
Membership No.: ACS 13709

Place : Hyderabad

Date : April 21, 2026